Abstract
Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.
Original language | English |
---|---|
Journal | Oncology |
Volume | 29 |
Issue number | 12 |
State | Published - 1 Dec 2015 |